Sinovac Biotech Ltd Stock Price, News & Analysis

Sinovac Biotech (NASDAQ: SVA) announced the first meeting of its newly elected Board of Directors following the July 8, 2025 Special Meeting. The new board was elected with 33,248,861 votes (54.71%) of total votes. Mr. Andrew Y. Yan, Managing Partner of SAIF Partners, was elected as Chairman of the Board.

The Board outlined key priorities including exploring future dividend plans, appointing a new auditor to resume NASDAQ trading, resolving ongoing shareholder litigations, and restoring stable operations. The Board confirmed Mr. Yin Weidong will continue as Executive Director and CEO of the company.

SINOVAC Biotech (NASDAQ: SVA) strongly denounces recent claims made by SAIF and the Imposter Former Board regarding a Special Meeting of Shareholders. The company's Chairman Chiang Li validly adjourned the July 8, 2025 meeting pending litigation resolution in Antigua concerning 11.8 million disputed PIPE shares issued to the Dissenting Investor Group.

According to Georgeson, SINOVAC's proxy solicitor, the company's White Proxy Card received strong support from valid shareholders before the adjournment. The current Board maintains it is the only legitimate governing body and accuses SAIF of conducting unauthorized vote tallying and making illegal claims about reconvening the meeting.

The company is evaluating legal remedies against SAIF and the Imposter Former Board in both Antigua and the United States while working to implement the UK Privy Council's judgment regarding the PIPE shares validity.

SINOVAC Biotech (NASDAQ: SVA) has announced the distribution process of its previously declared US$55.00 per common share special cash dividend to shareholders of record as of July 7, 2025. The payment process varies based on shareholding type:

For record holders with amounts under US$100 million, dividend checks will be sent via FedEx/UPS on July 9, 2025. Larger amounts will be wire transferred. Shareholders holding shares through brokers will receive payments once their brokers submit the required broker letter to the Paying Agent, with distributions beginning July 9, 2025.

SINOVAC Biotech (NASDAQ: SVA) announced the adjournment of its Special Meeting of Shareholders due to ongoing litigation regarding the validity of PIPE shares issued to Advantech/Prime and Vivo Capital. On July 7, 2025, the Antigua Court granted an interim injunction prohibiting PIPE shareholders from voting, but the Eastern Caribbean Court of Appeal later issued a temporary stay of this injunction.

The controversy stems from a 2018 PIPE transaction authorized by a former board that was deemed an "Imposter Board" by the UK Privy Council in January 2025. The current Board continues to govern SINOVAC and has begun distributing a special cash dividend of US$55.00 per common share. The company is working with NASDAQ to resume trading and exploring a potential Hong Kong Stock Exchange listing.

Sinovac Biotech (NASDAQ:SVA) shareholders have voted to approve significant changes in company leadership at a Special Meeting. The shareholders supported SAIF Partners' proposals to remove incumbent directors and elect their slate of ten new director nominees to the Board.

The meeting, initially attempted to be adjourned by incumbent Chairman Chiang Li, continued under the direction of Director Mr. Yuk Lam Lo. The newly elected directors have committed to executing the announced dividend payout and working towards resuming trading of Sinovac's common shares to enhance shareholder value.

Sinovac Biotech (NASDAQ:SVA) received a favorable ruling from the Eastern Caribbean Supreme Court regarding shareholder voting rights. The Court granted a motion to stay an injunction that was sought by 1Globe, which would have prevented certain shareholders from participating in a July 8th shareholder meeting.

The Court's decision specifically confirmed that Vivo Capital and Prime Success are permitted to attend and vote as valid shareholders. Vivo Capital, a healthcare-focused investment firm, emphasized its positive contributions since its 2018 investment, including support for CoronaVac development, while criticizing 1Globe's acquisition of control through alleged improper conduct.

Vivo Capital stated its commitment to restoring trust in Sinovac's governance and working toward resuming trading and returning cash to shareholders.

SINOVAC Biotech (NASDAQ: SVA) has issued a final reminder to shareholders ahead of their Special Meeting on July 8, 2025, urging them to vote AGAINST proposals 1 and 2 on the WHITE proxy card. Leading proxy advisory firms ISS and Glass Lewis have recommended shareholders vote against the election of the Reconstituted Imposter Former Board Slate.

The meeting will be held in Antigua and Barbuda with online participation available. Due to venue capacity limitations, shareholders are encouraged to participate electronically by registering at www.cesonlineservices.com/sva25_vm before the July 7 deadline.

Both ISS and Glass Lewis support the current board, noting their efforts to pay fair dividends to shareholders and resume share trading. They criticized the former board for enabling dividend payments to SLS minority shareholders while withholding dividends from SVA shareholders.

SINOVAC Biotech (NASDAQ: SVA) announced that the U.S. District Court for Massachusetts has denied Vivo Capital's petition against 1Globe Capital regarding shareholder votes and corporate governance. This marks the fourth failed legal attempt by the Dissenting Investor Group (Advantech/Prime and Vivo Capital) to prevent the distribution of a US$55.00 per share special cash dividend.

The ruling follows the UK Privy Council's January 2025 decision that deemed the former board an "Imposter Board" and validated 1Globe's position. The company revealed that the Dissenting Investor Group, along with the former board, had previously attempted a below-market privatization, executed an invalid PIPE transaction, and received over US$1 billion in distributions while common shareholders received nothing.

SINOVAC urges shareholders to vote by July 8 to maintain the current Board, which has announced plans for an additional US$11.00 per share dividend and implementation of a regular dividend policy.

Sinovac Biotech (NASDAQ:SVA) announced that the U.S. District Court of Massachusetts has granted a preliminary injunction against 1Globe Capital and Jiaqiang Li, requiring them to cease making misleading statements about their Sinovac shareholdings. The Court found that 1Globe likely violated disclosure obligations by failing to properly disclose beneficial ownership interests and group affiliations.

The ruling mandates 1Globe to file updated Schedule 13D disclosures within 5 days. The Court cited multiple violations, including undisclosed family member positions and documented instances of forged documents in 2018 and 2020. The decision comes ahead of a Special Meeting of Shareholders on July 8, 2025, where Vivo Capital supports SAIF Partners' slate of board nominees to restore proper governance and enable Sinovac to retain a new auditor, implement a dividend plan, and restore NASDAQ trading.